Azur Pharma plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Azur Pharma plc
Pandemic-related collaborations between Hoth/VCU; Sorrento/Mt. Sinai Health; Audax/Northeastern U.; Alkido/U. of Maryland, Baltimore; Active Motif/Hisun BioRay/Fudan U. and more.
An alliance of Deerfield and the Broad Institute to accelerate research into high-mortality diseases identifies its first two research projects, while Janssen and UPenn look into gene therapy for Alzheimer's disease.
The National Institutes of Health (NIH) plans to provide $2.2 million in funding over the next five years for the development of three innovative "co-robot" projects: an affordable hand-worn device to help the visually impaired grasp objects, a smart-walker to increase mobility in the elderly and a social-robot companion for children. The hand-worn device, which can detect a small object and help the blind user maintain alignment with the object while approaching it, has a global market potential of nearly $20 billion.
Merger & acquisition (M&A) activity among pharmaceutical and bioscience companies has shown no signs of slowing down. More importantly, even though AstraZeneca's rejection of Pfizer's $120bn plus takeover overture has meant that 2014 cannot boast the largest ever M&A deal, the number of $10bn transactions this year has still surpassed that of 2012 and 2013.